American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists最新文献

{"title":"A guide to implementing an emergency medicine advanced pharmacy practice experience.","authors":"David E Zimmerman, Anne E Zepeski, Christopher J Edwards","doi":"10.1093/ajhp/zxaf140","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf140","url":null,"abstract":"","PeriodicalId":520552,"journal":{"name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From policy to practice: Implementation of emergency medicine pharmacist medication administration.","authors":"Joseph Guidos, Ravipal Singh, Andrew Smith, Ryan Feldman","doi":"10.1093/ajhp/zxaf130","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf130","url":null,"abstract":"<p><strong>Purpose: </strong>This article aims to provide a framework, checklist, and successful case examples in different regulatory environments to assist stakeholders in formalizing a process for emergency medicine pharmacist medication administration.</p><p><strong>Summary: </strong>The emergency department is a complex and dynamic environment where competing resuscitation priorities can create scenarios in which the demand for critical medications exceeds the availability of skilled healthcare workers to administer them. Medications are a cornerstone of treating acute medical conditions and preventing patient deterioration. Many emergency medicine pharmacists regularly administer medications in the emergency department as part of their professional duties, enhancing task distribution and optimizing resuscitation workflows. Despite its value, the implementation of pharmacist medication administration varies widely across regulatory landscapes. This article explores the benefits of emergency medicine pharmacist medication administration, practical considerations for implementation, potential barriers, and viable solutions. A primary advantage of this practice is the improvement in task distribution and workflow flexibility, which accelerates medication administration during critical, time-sensitive situations and resource shortages. However, challenges persist, including variability in state-specific scope-of-practice regulations, navigating undefined areas of practice, securing clinical and administrative support, and addressing liability and policy development concerns.</p><p><strong>Conclusion: </strong>Empowering emergency medicine pharmacists to administer medications in the emergency department is a significant opportunity to enhance patient care. Solutions, such as clarifying local scope of practice, highlighting benefits, fostering collaborative environments, and developing clear policies are essential steps in overcoming barriers to allow emergency medicine pharmacist medication administration and for the expansion of the ever-evolving pharmacist's role.</p>","PeriodicalId":520552,"journal":{"name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144201304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2024 updated Basel Statements on the future of hospital pharmacy.","authors":"Michael Stepanovic, Racha Dabliz, Robert J Moss, Rebekah Moles, Regis Vaillancourt, Jonathan Penm, Stephen F Eckel","doi":"10.1093/ajhp/zxaf131","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf131","url":null,"abstract":"<p><strong>Purpose: </strong>The Hospital Pharmacy Section of the International Pharmaceutical Federation (FIP) revised the Basel Statements on the Future of Hospital Pharmacy to ensure they reflect contemporary challenges, advancements, and trends in hospital pharmacy practice. The process involved global pharmacy leaders, ensuring the updated statements are relevant across diverse healthcare systems.</p><p><strong>Methods: </strong>A multiphase, evidence-driven revision process was employed, beginning with a gap analysis, document mapping, and membership survey that has been previously described. This article contains the final phase the statement update process, which included a workshop at the 81st FIP World Congress in which 92 pharmacy leaders from all World Health Organization (WHO) regions participated. Participants engaged in independent review, group discussions, and a modified Delphi process to assess consensus on the revisions. An a priori consensus threshold of 80% was set for the Delphi study.</p><p><strong>Results: </strong>Workshop participants, with a mean of 17.7 (SD, 11.4) years of pharmacist experience, contributed to comprehensive revisions, including 2 new Basel Statements and the consolidation of 2 existing statements. The Delphi voting achieved consensus on all revised Basel Statements, with 100% of revisions meeting the 80% threshold. Major updates focused on medication safety leadership, workforce protection, and the integration of technology. The revisions address evolving challenges in pharmacy practice, including safety lessons, the rise of stewardship teams, advancements in informatics, and the impacts of coronavirus disease 2019.</p><p><strong>Conclusion: </strong>The revised Basel Statements provide an updated framework for hospital pharmacy practice. Future updates should follow similar methodology, focusing on integrating feedback and developing practical guides to improve implementation and utilization of the Basel Statements.</p>","PeriodicalId":520552,"journal":{"name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olipudase Alfa-rpcp.","authors":"","doi":"10.1093/ajhp/zxac273","DOIUrl":"https://doi.org/10.1093/ajhp/zxac273","url":null,"abstract":"","PeriodicalId":520552,"journal":{"name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","volume":" ","pages":"2200-2203"},"PeriodicalIF":2.7,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40339923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication adverse events in the ambulatory setting: A mixed-methods analysis.","authors":"Joanne Wong,&nbsp;Shin-Yu Lee,&nbsp;Urmimala Sarkar,&nbsp;Anjana E Sharma","doi":"10.1093/ajhp/zxac253","DOIUrl":"https://doi.org/10.1093/ajhp/zxac253","url":null,"abstract":"<p><strong>Purpose: </strong>To characterize ambulatory care adverse drug events reported to the Collaborative Healthcare Patient Safety Organization (CHPSO), a network of 400 hospitals across the United States, and identify addressable contributing factors.</p><p><strong>Methods: </strong>We abstracted deidentified ambulatory care CHPSO reports compiled from May 2012 to October 2018 that included medication-related adverse events to identify implicated medications and contributing factors. We dual-coded 20% of the sample. We quantitatively calculated co-occurring frequent item sets of contributing factors and then applied a qualitative thematic analysis of co-occurring sets of contributing factors for each drug class using an inductive analytic approach to develop formal themes.</p><p><strong>Results: </strong>Of 1,244 events in the sample, 208 were medication related. The most commonly implicated medication classes were anticoagulants (n = 97, or 46% of events), antibiotics (n = 24, 11%), hypoglycemics (n = 19, 9%), and opioids (n = 17, 8%). For anticoagulants, timely follow-up on supratherapeutic international normalized ratio (INR) values occurred before the development of symptoms. Incident reports citing antibiotics often described prescribing errors and failure to review clinical contraindications. Reports citing hypoglycemic drugs described low blood sugar events due to a lack of patient education or communication. Reports citing opioids described drug-drug interactions, commonly involving benzodiazepines.</p><p><strong>Conclusion: </strong>Ambulatory care prescribing clinicians and community pharmacists have the potential to mitigate harm related to anticoagulants, antibiotics, hypoglycemics, and opioids. Recommendations include increased follow-up for subtherapeutic INRs, improved medical record integration and chart review for antibiotic prescriptions, enhanced patient education regarding hypoglycemics, and alerts to dissuade coprescription of opioids and benzodiazepines.</p>","PeriodicalId":520552,"journal":{"name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","volume":" ","pages":"2230-2243"},"PeriodicalIF":2.7,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40378461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dextromethorphan Hydrobromide and Bupropion Hydrochloride.","authors":"","doi":"10.1093/ajhp/zxac292","DOIUrl":"https://doi.org/10.1093/ajhp/zxac292","url":null,"abstract":"","PeriodicalId":520552,"journal":{"name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","volume":" ","pages":"2193-2199"},"PeriodicalIF":2.7,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40340795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacy leaders find common ground on population health.","authors":"Kate Traynor","doi":"10.1093/ajhp/zxac311","DOIUrl":"https://doi.org/10.1093/ajhp/zxac311","url":null,"abstract":"","PeriodicalId":520552,"journal":{"name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","volume":" ","pages":"2204-2205"},"PeriodicalIF":2.7,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35345754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study.","authors":"Arielle R Nagler,&nbsp;Leora I Horwitz,&nbsp;Simon Jones,&nbsp;Christopher M Petrilli,&nbsp;Eduardo Iturrate,&nbsp;Jennifer L Lighter,&nbsp;Michael Phillips,&nbsp;Brian P Bosworth,&nbsp;Bruce Polsky,&nbsp;Frank M Volpicelli,&nbsp;Isaac Dapkins,&nbsp;Anand Viswanathan,&nbsp;Fritz François,&nbsp;Gary Kalkut","doi":"10.1093/ajhp/zxac295","DOIUrl":"https://doi.org/10.1093/ajhp/zxac295","url":null,"abstract":"<p><strong>Purpose: </strong>Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on clinical outcomes within 30 days of COVID-19 diagnosis.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted at a single academic medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19-specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from the date of COVID-19 diagnosis.</p><p><strong>Results: </strong>A total of 1,344 mAb-treated patients were propensity matched to 1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, 0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice (RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the risk of ED presentation and hospital admission within 30 days of diagnosis.</p>","PeriodicalId":520552,"journal":{"name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","volume":" ","pages":"2222-2229"},"PeriodicalIF":2.7,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619808/pdf/zxac295.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33512105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2022 ASHP Guidelines on Preventing Diversion of Controlled Substances: An updated roadmap for practice.","authors":"Daniel J Cobaugh,&nbsp;Eric Maroyka","doi":"10.1093/ajhp/zxac296","DOIUrl":"https://doi.org/10.1093/ajhp/zxac296","url":null,"abstract":"","PeriodicalId":520552,"journal":{"name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","volume":" ","pages":"2191-2192"},"PeriodicalIF":2.7,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between advanced pharmacy practice experience grading schemes and pharmacy residency match rates.","authors":"Jane Shtaynberg,&nbsp;Maryann Skrabal,&nbsp;Tina Kanmaz,&nbsp;C Leiana Oswald,&nbsp;Jennifer Prisco,&nbsp;Jennie B Jarrett,&nbsp;Cheryl Clarke,&nbsp;Valerie Ruehter,&nbsp;Eric Gilliam,&nbsp;Angela Clauson,&nbsp;Guogen Shan","doi":"10.1093/ajhp/zxac254","DOIUrl":"https://doi.org/10.1093/ajhp/zxac254","url":null,"abstract":"<p><strong>Purpose: </strong>To determine the relationship of advanced pharmacy practice experience (APPE) grading schemes and other pharmacy program variables (ie, program age and funding) with pharmacy residency match rates.</p><p><strong>Summary: </strong>A 12-question survey was disseminated to experiential administrators of pharmacy programs in October 2018. Respondents identified their program's APPE grading scheme (pass/fail, letter grades, or other) and associated pros and cons. Responding programs were categorized by age and funding status. Survey responses were correlated with the American Society of Health-System Pharmacists residency match rates for 2016 through 2018. Data were analyzed using descriptive statistics and logistic regression models as well as by attributes via thematic analysis. Most pharmacy programs (62%) reported using letter grades for APPEs compared to pass/fail (30%) or other (8%) schemes. Pharmacy programs using pass/fail grading were more likely to have students match to postgraduate year 1 (PGY1) (P < 0.001) and postgraduate year 2 (PGY2) (P = 0.0074) residencies. Older pharmacy programs for each grading scheme were more likely to have higher match rates; however, for PGY1 match rates, older programs utilizing letter grades correlated to lower match rates than those utilizing pass/fail grading (P < 0.0001). Likewise, both public and private pharmacy programs using pass/fail grading had higher PGY1 match rates than those using letter grades (P = 0.0006 and P = 0.0014).</p><p><strong>Conclusion: </strong>Pass/fail grading in APPEs does not hinder PGY1 or PGY2 residency placement compared to other grading schemes both overall and in combination with certain pharmacy program variables. Grading scheme strengths and weaknesses should be considered when deciding on optimal assessment strategies for APPEs and when evaluating candidates for residencies.</p>","PeriodicalId":520552,"journal":{"name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","volume":" ","pages":"2261-2270"},"PeriodicalIF":2.7,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33455847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}